The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month.
News & Analysis: Acadia Pharmaceuticals
ACAD earnings call for the period ending March 31, 2019.
Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.
The company's comeback story continued to gain momentum last month.
ACAD earnings call for the period ending December 31, 2018.
Acadia Pharmaceuticals, Vanguard FTSE Emerging Markets, and Kraft Heinz are attracting Wall Street's best.
The pharma company was an easy target for Mr. Market during last month's sell-off, but it appears well positioned for a rebound in 2019.
Shares rebound after the company announces the pricing details of its common stock offering.
Shares take a dive after management announces a fresh capital raise. Here's what investors need to know.
The FDA issued a positive statement on the company's drug for Parkinson's disease psychosis, but investors still need to watch one important metric.